Search
Crovalimab
go.drugbank.com/drugs/DB16128ApprovedInvestigational[A263958] It soon gained its approval in Japan in the next month,[A263958] and in the USA in June of the same year. … [L50908] First developed by Chugai Pharmaceutical, in collaboration with Roche, crovalimab was first approved in China in February 2024 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Peramivir
go.drugbank.com/drugs/DB06614ApprovedInvestigationalThe development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. … The injectable intravenous formulation of peramivir was approved by the FDA in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic
Chloroprocaine
go.drugbank.com/drugs/DB01161ApprovedInvestigationalBoth can be given as intrathecal injections for peripheral and central nerve block, but only the preservative-free formulation can be used for lumbar and caudal epidural blocks. … [A252952,L43382] Topical chloroprocaine for ophthalmic use was approved by the FDA in September 2022 for ocular surface anesthesia.[L43387]
Dextrose, unspecified form
go.drugbank.com/drugs/DB09341ApprovedInvestigationalVet approvedGlucose is a simple sugar (monosaccharide) generated during phosynthesis involving water, carbon and sunlight in plants. It is produced in humans via hepatic gluconeogenesis and breakdown of polymeric glucose forms (glycogenolysis). It c...
Mixtures: CAPD/DPCA 3 SLEEP SAFE PERITONEAL DIALYSIS SOLUTION, CAPD/DPCA 2 SLEEP SAFE PERITONEAL DIALYSIS SOLUTIONErythromycin
go.drugbank.com/drugs/DB00199ApprovedInvestigationalVet approved[L5245] Erythromycin is widely used for treating a variety of infections, including those caused by gram-positive and gram-negative bacteria. … Erythromycin is a bacteriostatic antibiotic drug produced by a strain of Saccharopolyspora erythraea (formerly Streptomyces erythraeus) and belongs to the macrolide group of antibiotics which consists
Viloxazine
go.drugbank.com/drugs/DB09185ApprovedInvestigationalWithdrawnIt was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy. … In April 2021, an extended-release formulation of viloxazine under the brand name QELBREE was approved by the FDA for the treatment of attention deficit hyperactivity disorder (ADHD).[A247985]
Avalglucosidase alfa
go.drugbank.com/drugs/DB16099ApprovedInvestigational[L35160] Avalglucosidase alfa was approved by Health Canada on November 15, 2021 for the treatment of patients older than six months of age with late-onset Pompe disease. … [A232960] On August 6, 2021, avalglucosidase alfa-ngpt was approved by the FDA under the market name Nexviazyme to treat patients one year of age and older with late-onset Pompe disease.
Zomepirac
go.drugbank.com/drugs/DB04828ApprovedWithdrawnThe manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.
Mavacamten
go.drugbank.com/drugs/DB14921ApprovedInvestigational[A248440] Mavacamten was also approved by Health Canada in October 2022 and by EMA in July 2023 for the same indication.[L44106,L47471] … It received initial US FDA approval in 2022, and it is one of the first myosin inhibitors to be used in humans.
Tralokinumab
go.drugbank.com/drugs/DB12169ApprovedInvestigationalUS in December 2021. … It neutralizes IL-13 activity by inhibiting its ability to bind with receptors, thus helping to alleviate AD symptoms.